Growth velocity in transfusion dependent prepubertal thalassemia patients: results from a thalassemia center in Malaysia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Growth impairment is commonly seen in children with thalassemia despite regular blood transfusions and desferrioxamine treatments. We investigated the growth velocity of 26 prepubertal patients with beta-thalassemia or HbE-beta thalassemia who were transfusion dependent aged between 2 and 13 years. The prevalence of impaired growth velocity (ie, growth velocity less than the third percentile) amongst the transfusion dependent prepubertal thalassemics was 57.7% compared to 19.2% in the control group. The mean height velocity of the thalassemics was 11.1% less than controls but this difference was not statistically significant (4.23cm/year vs 4.76cm/year, p = 0.08). The mean serum ferritin level of the thalassemics with a height < 3rd percentile was higher compared to those with a height > 3rd percentile (4,567.0 vs 2,271.0, p = 0.01). Our study showed that there was a high prevalence of impaired growth velocity amongst our transfusion dependent prepubertal thalassemics. This highlights the problem of inadequate chelation therapy, and compliance with chelation therapy amongst our patients. This study emphasizes the importance of monitoring growth parameters and optimal iron chelation therapy in these patients.

Original languageEnglish
Pages (from-to)900-905
Number of pages6
JournalThe Southeast Asian journal of tropical medicine and public health
Volume39
Issue number5
Publication statusPublished - 1 Sep 2008

Fingerprint

Thalassemia
Malaysia
Chelation Therapy
Growth
beta-Thalassemia
Deferoxamine
Ferritins
Blood Transfusion
Iron
Control Groups
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{5a50a2e0206e419b84932b0093295545,
title = "Growth velocity in transfusion dependent prepubertal thalassemia patients: results from a thalassemia center in Malaysia",
abstract = "Growth impairment is commonly seen in children with thalassemia despite regular blood transfusions and desferrioxamine treatments. We investigated the growth velocity of 26 prepubertal patients with beta-thalassemia or HbE-beta thalassemia who were transfusion dependent aged between 2 and 13 years. The prevalence of impaired growth velocity (ie, growth velocity less than the third percentile) amongst the transfusion dependent prepubertal thalassemics was 57.7{\%} compared to 19.2{\%} in the control group. The mean height velocity of the thalassemics was 11.1{\%} less than controls but this difference was not statistically significant (4.23cm/year vs 4.76cm/year, p = 0.08). The mean serum ferritin level of the thalassemics with a height < 3rd percentile was higher compared to those with a height > 3rd percentile (4,567.0 vs 2,271.0, p = 0.01). Our study showed that there was a high prevalence of impaired growth velocity amongst our transfusion dependent prepubertal thalassemics. This highlights the problem of inadequate chelation therapy, and compliance with chelation therapy amongst our patients. This study emphasizes the importance of monitoring growth parameters and optimal iron chelation therapy in these patients.",
author = "Hamidah Alias and Arini, {M. I.} and {Abdul Latiff}, Zarina and {Syed Zakaria}, {Syed Zulkifli} and {A. Jamal}, {A. Rahman}",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "39",
pages = "900--905",
journal = "The Southeast Asian journal of tropical medicine and public health",
issn = "0125-1562",
publisher = "Southeast Asian Ministers of Education Organisation",
number = "5",

}

TY - JOUR

T1 - Growth velocity in transfusion dependent prepubertal thalassemia patients

T2 - results from a thalassemia center in Malaysia

AU - Alias, Hamidah

AU - Arini, M. I.

AU - Abdul Latiff, Zarina

AU - Syed Zakaria, Syed Zulkifli

AU - A. Jamal, A. Rahman

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Growth impairment is commonly seen in children with thalassemia despite regular blood transfusions and desferrioxamine treatments. We investigated the growth velocity of 26 prepubertal patients with beta-thalassemia or HbE-beta thalassemia who were transfusion dependent aged between 2 and 13 years. The prevalence of impaired growth velocity (ie, growth velocity less than the third percentile) amongst the transfusion dependent prepubertal thalassemics was 57.7% compared to 19.2% in the control group. The mean height velocity of the thalassemics was 11.1% less than controls but this difference was not statistically significant (4.23cm/year vs 4.76cm/year, p = 0.08). The mean serum ferritin level of the thalassemics with a height < 3rd percentile was higher compared to those with a height > 3rd percentile (4,567.0 vs 2,271.0, p = 0.01). Our study showed that there was a high prevalence of impaired growth velocity amongst our transfusion dependent prepubertal thalassemics. This highlights the problem of inadequate chelation therapy, and compliance with chelation therapy amongst our patients. This study emphasizes the importance of monitoring growth parameters and optimal iron chelation therapy in these patients.

AB - Growth impairment is commonly seen in children with thalassemia despite regular blood transfusions and desferrioxamine treatments. We investigated the growth velocity of 26 prepubertal patients with beta-thalassemia or HbE-beta thalassemia who were transfusion dependent aged between 2 and 13 years. The prevalence of impaired growth velocity (ie, growth velocity less than the third percentile) amongst the transfusion dependent prepubertal thalassemics was 57.7% compared to 19.2% in the control group. The mean height velocity of the thalassemics was 11.1% less than controls but this difference was not statistically significant (4.23cm/year vs 4.76cm/year, p = 0.08). The mean serum ferritin level of the thalassemics with a height < 3rd percentile was higher compared to those with a height > 3rd percentile (4,567.0 vs 2,271.0, p = 0.01). Our study showed that there was a high prevalence of impaired growth velocity amongst our transfusion dependent prepubertal thalassemics. This highlights the problem of inadequate chelation therapy, and compliance with chelation therapy amongst our patients. This study emphasizes the importance of monitoring growth parameters and optimal iron chelation therapy in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84918500680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918500680&partnerID=8YFLogxK

M3 - Article

C2 - 19058587

AN - SCOPUS:52649165079

VL - 39

SP - 900

EP - 905

JO - The Southeast Asian journal of tropical medicine and public health

JF - The Southeast Asian journal of tropical medicine and public health

SN - 0125-1562

IS - 5

ER -